Prophase Labs Stock Performance
| PRPH Stock | USD 0.69 0.28 28.87% |
The company holds a Beta of 2.01, which implies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, ProPhase Labs will likely underperform. At this point, ProPhase Labs has a negative expected return of -2.45%. Please make sure to check ProPhase Labs' total risk alpha, kurtosis, as well as the relationship between the Kurtosis and day typical price , to decide if ProPhase Labs performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days ProPhase Labs has generated negative risk-adjusted returns adding no value to investors with long positions. Despite uncertain performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in January 2026. The recent confusion may also be a sign of long-lasting up-swing for the firm traders. ...more
Last Split Factor 1:10 | Dividend Date 2022-06-03 | Ex Dividend Date 2022-05-24 | Last Split Date 2025-12-22 |
1 | ProPhase Labs engages RedChip to lead investor relations efforts PRPH | 10/28/2025 |
2 | How strong is ProPhase Labs Inc. stock revenue growth - July 2025 Rallies Long-Term Investment Growth Plans - newser.com | 11/10/2025 |
3 | Reversal indicators forming on ProPhase Labs Inc. stock - Trade Risk Summary Free High Return Stock Watch Alerts - newser.com | 11/13/2025 |
4 | Sykon Capital LLC Acquires Shares of 644,795 ProPhase Labs, Inc. PRPH | 11/17/2025 |
5 | A Peek at ProPhase Labss Future Earnings | 11/18/2025 |
6 | ProPhase Labs GAAP EPS of -0.16, revenue of 0.88M | 11/19/2025 |
7 | ProPhase Labs Posts Quarterly Earnings Results, Misses Expectations By 0.05 EPS | 11/20/2025 |
8 | Acquisition by Ted Karkus of 500000 shares of ProPhase Labs at 0.6 subject to Rule 16b-3 | 11/21/2025 |
9 | Join ProPhase Labs Exclusive Live Investor Webinar and QA Session on December 1 | 11/26/2025 |
10 | Prophase Labs Faces Unsealed Civil Action Disclosure - MSN | 12/15/2025 |
| Begin Period Cash Flow | 1.6 M | |
| Total Cashflows From Investing Activities | 2.4 M |
ProPhase Labs Relative Risk vs. Return Landscape
If you would invest 428.00 in ProPhase Labs on September 25, 2025 and sell it today you would lose (359.00) from holding ProPhase Labs or give up 83.88% of portfolio value over 90 days. ProPhase Labs is currently does not generate positive expected returns and assumes 8.6778% risk (volatility on return distribution) over the 90 days horizon. In different words, 77% of stocks are less volatile than ProPhase, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
ProPhase Labs Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for ProPhase Labs' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as ProPhase Labs, and traders can use it to determine the average amount a ProPhase Labs' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.2824
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | PRPH |
Based on monthly moving average ProPhase Labs is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of ProPhase Labs by adding ProPhase Labs to a well-diversified portfolio.
ProPhase Labs Fundamentals Growth
ProPhase Stock prices reflect investors' perceptions of the future prospects and financial health of ProPhase Labs, and ProPhase Labs fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on ProPhase Stock performance.
| Return On Equity | -2.2 | ||||
| Return On Asset | -0.23 | ||||
| Operating Margin | (5.40) % | ||||
| Current Valuation | 11.34 M | ||||
| Shares Outstanding | 4.19 M | ||||
| Price To Earning | 6.59 X | ||||
| Price To Book | 0.59 X | ||||
| Price To Sales | 0.57 X | ||||
| Revenue | 6.77 M | ||||
| Gross Profit | 987 K | ||||
| EBITDA | (32.34 M) | ||||
| Net Income | (49.52 M) | ||||
| Cash And Equivalents | 27.5 M | ||||
| Cash Per Share | 1.72 X | ||||
| Total Debt | 24.57 M | ||||
| Debt To Equity | 0.19 % | ||||
| Current Ratio | 4.20 X | ||||
| Book Value Per Share | 1.65 X | ||||
| Cash Flow From Operations | (17.54 M) | ||||
| Earnings Per Share | (19.80) X | ||||
| Market Capitalization | 2.88 M | ||||
| Total Asset | 63.2 M | ||||
| Retained Earnings | (58.39 M) | ||||
| Working Capital | (1.5 M) | ||||
| Current Asset | 9.73 M | ||||
| Current Liabilities | 6.25 M | ||||
About ProPhase Labs Performance
By evaluating ProPhase Labs' fundamental ratios, stakeholders can gain valuable insights into ProPhase Labs' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if ProPhase Labs has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if ProPhase Labs has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 60.29 | 57.27 | |
| Return On Tangible Assets | (1.11) | (1.05) | |
| Return On Capital Employed | (1.24) | (1.18) | |
| Return On Assets | (0.84) | (0.80) | |
| Return On Equity | (7.26) | (6.89) |
Things to note about ProPhase Labs performance evaluation
Checking the ongoing alerts about ProPhase Labs for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for ProPhase Labs help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| ProPhase Labs generated a negative expected return over the last 90 days | |
| ProPhase Labs has high historical volatility and very poor performance | |
| ProPhase Labs has some characteristics of a very speculative penny stock | |
| ProPhase Labs has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 6.77 M. Net Loss for the year was (49.52 M) with profit before overhead, payroll, taxes, and interest of 987 K. | |
| ProPhase Labs currently holds about 27.5 M in cash with (17.54 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.72, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| ProPhase Labs has a poor financial position based on the latest SEC disclosures | |
| Latest headline from news.google.com: Prophase Labs Faces Unsealed Civil Action Disclosure - MSN |
- Analyzing ProPhase Labs' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether ProPhase Labs' stock is overvalued or undervalued compared to its peers.
- Examining ProPhase Labs' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating ProPhase Labs' management team can have a significant impact on its success or failure. Reviewing the track record and experience of ProPhase Labs' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of ProPhase Labs' stock. These opinions can provide insight into ProPhase Labs' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for ProPhase Stock analysis
When running ProPhase Labs' price analysis, check to measure ProPhase Labs' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ProPhase Labs is operating at the current time. Most of ProPhase Labs' value examination focuses on studying past and present price action to predict the probability of ProPhase Labs' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ProPhase Labs' price. Additionally, you may evaluate how the addition of ProPhase Labs to your portfolios can decrease your overall portfolio volatility.
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Stocks Directory Find actively traded stocks across global markets | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets |